Drugs in the Treatment of Primary Pulmonary Arterial Hypertension

  • C. Marini
  • G. Di Ricco
  • C. Guintini
Part of the Ettore Majorana International Science Series book series (EMISS, volume 14)


Primary pulmonary arterial hypertension (PPH) should be suspected whenever the following features are present:
  1. 1

    history of progressive exertional dyspnoea, fatigue and repeated syncopal attacks especially in by young women.

  2. 2

    physical signs of pulmonary hypertension (increase of intensity of cardiac second sound) often associated with signs of low cardiac output (increase of intensity of cardiac first sound).

  3. 3

    ECG changes consistent with right ventricular hypertrophy.

  4. 4

    X-ray evidence of enlargement of right heart cavities and main pulmonary artery with normal left atrium.

  5. 5

    normal or only slightly altered pulmonary function.



Pulmonary Hypertension Pulmonary Arterial Hypertension Cardiac Index Pulmonary Artery Pressure Pulmonary Vascular Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lee, T. D. Jr., Roveti, G. C., Ross, R. S. 1963. The hemodynamic effects of Isoproterenol on pulmonary hypertension in man. Am. Heart J. 65 (3), 361–367.CrossRefGoogle Scholar
  2. 2.
    Rao, B. N. S., Moller, J. H. and Edwards, J. E. 1969. Primary pulmonary hypertension in a child. Response to pharmacologic agents. Circulation XL: 583–587.CrossRefGoogle Scholar
  3. 3.
    Shettigar, U. R., Hultgren, H. N., Specter, M., Martin, R. and Davies, D. H. 1976. Primary pulmonary hypertension. Favourable effect of Isoproterenol. N. Engl. J. Med., 295 (25), 1414–1415.CrossRefGoogle Scholar
  4. 4.
    Person, B. and Proctor, R. J. 1979. Primary pulmonary hypertension. Response to Indomethacin, Terbutaline and Isoproterenol. Chest, 76 (5), 601–603.CrossRefGoogle Scholar
  5. 5.
    Pantano, J. A. 1980. Isoproterenol in primary pulmonary hypertension. N. Engl. J. Med., 302 (16), 919–920.Google Scholar
  6. 6.
    Lupi-Herrera, E., Bialostozki, D. and Sobrino, A. The role of Isoproterenol in pulmonary artery hypertension of unknown etiology (primary). Short and long-term evaluation. Chest, 79 (3), 292–296.Google Scholar
  7. 7.
    Gould, L., Chokshi, A. B., Patel, S., Gomes, G. I. 1981. Hemodynamic evaluation of vasodilator drug therapy in primary pulmonary hypertension. Am. Heart J., 102 (2), 300.CrossRefGoogle Scholar
  8. 8.
    Rich, S., Levy, P. S., Rosen, K. M. 1982. A reassessment of the acute hemodynamic effects of vasodilators in primary pulmonary hypertension. Symposium on primary pulmonary hypertension. Wien, 18–20 March, Abstract book, page 39.Google Scholar
  9. 9.
    Dresdale, D. T., Schultz, M. and Michtom, R. J. 1951. Primary pulmonary hypertension: I. Clinical and hemodynamic study. Am. J. Med., 11, 686.CrossRefGoogle Scholar
  10. 10.
    Wade, G. and Ball, J. 1957. Unexplained pulmonary hypertension. Quart. J. Med., 26, 83.Google Scholar
  11. 11.
    Yu, P. N. 1958. Primary pulmonary hypertension: report of six cases and review of literature. Ann. Intern. Med., 49 (5), 1138–1159.Google Scholar
  12. 12.
    Gorlin, R., Clare, F. B., Zuska, J. J. 1958. Evidence of pulmonary vaso-constriction in man. Br. Heart J., 20, 346.CrossRefGoogle Scholar
  13. 13.
    Fennell, W. H., Farmer, J. A. Graf, R. H. and Young, J. B. 1982. Unanticipated response to alpha-adrenergic blockade in pulmonary hypertension. Chest, 81 (1), 128–129.CrossRefGoogle Scholar
  14. 14.
    Ruskin, J. N. and Hutter, A. M. 1979. Primary pulmonary hypertension treated with oral phentolamine. Ann. Intern. Med., 90, 772–774.Google Scholar
  15. 15.
    Se Do Cha., Kirschbaum, M., Maranhao, V., Paine, E., Gooch, A. S. 1979. Phentolamine for primary pulmonary hypertension. Ann. Intern. Med., 91 (6), 927–928.Google Scholar
  16. 16.
    Cohen, M. L. and Kronzon, I. 1981. Adverse hemodynamic effects of Phentolamine in primary pulmonary hypertension. Ann. Intern. Med., 95 (5), 591–592.Google Scholar
  17. 17.
    Landmark, K., Refsum, A. M., Simonsen, S. and Storstein, O. 1978. Verapamil and pulmonary hypertension. Acta Med. Scan., 204, 299–302.CrossRefGoogle Scholar
  18. 18.
    Camerini, F., Alberti, E., Klugmann, S., Salvi, A. 1980. Primary pulmonary hypertension: effects of nifedipine. Br. Heart J. 44, 352–356.CrossRefGoogle Scholar
  19. 19.
    Rozkovec, A., Stradling, J., Shepherd, G., Wilde, S., MacDermot, J., Oakley, C. N. and Dollery, C. T. 1982. Variable response to vasodilator therapy in primary pulmonary hypertension. Symposium on primary pulmonary hypertension, Wien, 1820 March. Abstracts book page 38.Google Scholar
  20. 20.
    Kambara, H., Fujimoto, K., Wakabayashi, A and Kawai, C. 1981. Primary pulmonary hypertension: beneficial therapy with diltiazem. Am. Heart J., 101 (2), 230–231.CrossRefGoogle Scholar
  21. 21.
    Crevey, B. J., Dantzker, D. R., Bower, J. S., Popat, K. D., Walker, S. D. 1982. Hemodynamic and gas exchange effects of intravenous Diltiazem in patients with pulmonary hypertension. Am. J. Cardiol., 49, 578–583.CrossRefGoogle Scholar
  22. 22.
    Rubin, L. J. and Peter, R. H. 1980. Oral hydralazine therapy for primary pulmonary hypertension. N. Engl. J. Med., 302 (2), 69–73.CrossRefGoogle Scholar
  23. 23.
    Lupi-Herrera, E., Sandoval, J., Seoane, M. and Bialostozky, D. 1982. The role of Hydralazine therapy for pulmonary arterial hypertension of unknown cause. Circulation, 65 (4), 645–650.CrossRefGoogle Scholar
  24. 24.
    Guadagni, D. N., Ikram, H., Maslowski, A. H. 1981. Haemodynamic effects of prostacyclin (PGI<sub>2</sub>) in pulmonary hypertension. Br. Heart J., 45, 385–388.CrossRefGoogle Scholar
  25. 25.
    Wang, S. W. S., Pohl, J.E.F., Rowlands, D. J. and Wade, G. 1978. Diazoxide in treatment of primary pulmonary hypertension. Br. Heart J., 40, 572–574.CrossRefGoogle Scholar
  26. 26.
    Rubino, J. M. and Schroeder, J. S. 1979. Diazoxide in treatment of primary pulmonary hypertension. Br. Heart J., 42, 362–363.CrossRefGoogle Scholar
  27. 27.
    Honey, M., Cotter, L., Davies, N. and Denison, D. 1980. Clinical and haemodynamic effects of diazoxide in primary pulmonary hype rtens ion. Thorax, 35, 269–276.CrossRefGoogle Scholar
  28. 28.
    Klinke, W.P. and Gilbert, J. A. L. 1980. Diazoxide in primary pulmonary hypertension. N. Engl. J. Med., 302 (2), 91–92.CrossRefGoogle Scholar
  29. 29.
    Hall, D. R., Petch, M. C. 1981. Remission of primary pulmonary hypertension during treatment with diazoxide. Br. Heart J., 282, 1118.Google Scholar
  30. 30.
    Buch, J., Wennevold, A. 1981. Hazards of diazoxide in pulmonary hypertension. Br. Heart J., 46, 401–403.CrossRefGoogle Scholar
  31. 31.
    Rich, S., Rosen, K. M. 1982. Captopril for primary pulmonary hypertension: the problem of variability in assessing chronic drug therapy. Symposium on primary pulmonary hypertension. Wien, 18–20 March. Abstracts book, page 29.Google Scholar
  32. 32.
    Ogata, T. and Watanabe, S. 1982. Pulmonary vascular changes in 32 autopsy cases with unexplained pulmonary hypertension in Japan. Symposium on primary pulmonary hypertension. Wien, 18–20 March. Abstracts book, page 4.Google Scholar
  33. 33.
    Bergofsky, E. H. 1980. Humoral control of the pulmonary circulation. Ann. Rev. Physiol., 42, 221–233.CrossRefGoogle Scholar
  34. 34.
    Zener, J and Harrison, D. C. 1973. Circulatory actions of Phentolamine before and after autonomic blockade. Cardiov. Res. 7, 748–754.CrossRefGoogle Scholar
  35. 35.
    Harris, P., Heat, D. 1977. The Human Pulmonary Circulation. 2nd Edition. Churchill Livingstone, Edinburgh, page 200.Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • C. Marini
    • 1
  • G. Di Ricco
    • 1
  • C. Guintini
    • 1
  1. 1.C. N. R. Institute of Clinical Physiology and 2nd Medical ClinicUniversity of PisaPisaItaly

Personalised recommendations